Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis
- Institution
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA
- Principal investigator
- Da Yang
- Funding
- $409K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
Enhancer RNAs Boost MYC-Chromatin Interaction to Regulate Gene Expression and Tumorigenesis Summary: Our long-term goal is to determine how MYC’s RNA binding function contributes to its role as a master regulator of gene expression in physiological and pathological conditions. In last three decades, MYC has been extensively studied as a DNA-binding transcription factor. However, whether MYC can interact with RNA and, if yes, how such interactions would contribute to MYC function are poorly understood. In our preliminary study, we have shown that MYC may be a novel RNA-binding protein with a preference to bind with enhancer RNAs (eRNAs). In addition to characterizing MYC as an RNA-binding protein, we have also identified a MYC-bound eRNA MERG1 that can regulate breast cancer growth via recruiting MYC to its cognate enhancer. With these observations, we hypothesize that (1) MYC is an RNA- binding protein and (2) eRNA-mediated MYC-chromatin binding is important for MYC’s transcriptional regulation and oncogenic function. We propose three specific aims to test our hypotheses. In Aim 1, we will investigate if MERG1 is an oncogenic eRNA in ER+ breast cancer. In aim 2, we will investigate the molecular mechanism of MYC’s RNA binding function. In aim 3, we will build MYC-eRNA regulatory network. Our project will add a new dimension to mechanistically study the MYC-mediated gene regulation. Successful completion of the project will establish novel tools to investigate MYC-RNA binding function for the broader MYC research community. The investigation of MYC RNA binding function will also lay the foundation to develop novel strategy to target MYC in cancer.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Pittsburgh at PittsburghNot yet scored
LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer
Da Yang · $378K · 2023–2028
- NIH · University of Pittsburgh at PittsburghNot yet scored
A novel lncRNA-responsive and xenobiotic receptor-mediated regulation of drug metabolism and disposition
Da Yang · $376K · 2020–2026
- NIH · University of Pittsburgh at Pittsburgh64
Core E: Omics Core
Sid E O'Bryant · $3.2M · 2020–2026